DIADIA0.74%
SPYSPY0.67%
QQQQQQ1.13%
Trending
Top trending tickerSMCISMCI0.82%
ORCLORCL8.88%
SPYSPY0.67%
DJTDJT1.28%
SMCXSMCX1.35%
UUUUUUUU4.97%
INTCINTC4.26%
TRLVTRLV3.56%
DVNDVN0.26%
DKNGDKNG1.56%
Top trending tickerSMCISMCI0.82%
ORCLORCL8.88%
SPYSPY0.67%
DJTDJT1.28%
SMCXSMCX1.35%
UUUUUUUU4.97%
INTCINTC4.26%
TRLVTRLV3.56%
DVNDVN0.26%
DKNGDKNG1.56%
homeSymbolANROnews
ANRO logo

ANROAlto Neuroscience Inc.

$19.68
$1.47
(6.95%)
Today
Closed $19.68
$0.38
(1.93%)
After Hours
Updated: 06:26 PM EDT
Reported EarningsMay 13
Mkt Cap$742.24M
Vol347,091.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

News
all
press releases
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. We are thrilled...
Business Wire
News Placeholder
More News
News Placeholder
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&S Alumni...
Business Wire
News Placeholder
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported...
Business Wire
News Placeholder
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...
Business Wire
News Placeholder
Alto Neuroscience (ANRO) Projected to Post Earnings on Wednesday
Alto Neuroscience (NYSE:ANRO) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...
MarketBeat
News Placeholder
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a...
Business Wire
News Placeholder
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rati...
MarketBeat
News Placeholder
Alto Neuroscience (NYSE:ANRO) Earns "Buy" Rating from Chardan Capital
Chardan Capital reaffirmed a "buy" rating and set a $30.00 target price on shares of Alto Neuroscience in a research report on Wednesday...
MarketBeat
News Placeholder
Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High - Still a Buy?
Alto Neuroscience (NYSE:ANRO) Sets New 52-Week High - Should You Buy...
MarketBeat
News Placeholder
Alto Neuroscience (NYSE:ANRO) Shares Down 7.2% - Here's Why
Alto Neuroscience (NYSE:ANRO) Shares Down 7.2% - Time to Sell...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.

Advertisement|Remove ads.